- Home
- / Hemogenyx Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Hemogenyx Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
£0
2024-10-29
Market Capitalization
£17.8 M
2024-10-29
CreditSafe Score
?
Score changed on Jun 06, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| GBP | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross profit | 91.0K | 213.0K | 85.0K | 172.0K | 7.0K | |||
| Operating expense total | 1.6M | 1.6M | 2.1M | 2.7M | 5.0M | 4.6M | 4.4M | 3.7M |
| Depreciation and amortization | 52.0K | 94.0K | 106.0K | 126.0K | 564.0K | 646.0K | 639.0K | 857.0K |
| EBITDA | (1.5M) | (1.4M) | (2.0M) | (2.5M) | (5.0M) | (4.6M) | (4.4M) | (3.6M) |
| EBIT | (1.6M) | (1.5M) | (2.1M) | (2.7M) | (5.5M) | (5.2M) | (5.0M) | (4.5M) |
| Interest income | 4.0K | 14.0K | 3.0K | |||||
| Interest expense | 1.0K | 31.0K | 33.0K | 2.6M | 316.0K | 272.0K | 230.0K | |
| Pre tax profit | (1.6M) | (1.5M) | (2.1M) | (5.1M) | (4.0M) | (6.7M) | (5.6M) | (9.8M) |
| Income tax expense | (44.0K) | (35.0K) | ||||||
| Net Income | (1.5M) | (1.5M) | (2.1M) | (5.1M) | (4.0M) | (6.7M) | (5.6M) | (9.8M) |